Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020;22:34-44.

Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66:18-22.

Kim D, Viswanathan K, Goyal A, Rao R. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2020;128(4):269-277.

Rotman JA, Dean KE, Magro C, Nuovo G, Bartolotta RJ. Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura. Skeletal Radiol. 2020;49(11):1879-1884.

2019

Clijsters L, Hoencamp C, Calis JJ, Marzio A, Handgraaf SM, Cuitiño MC, et al. Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 2019;74(6):1264-1277.e7.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2019.

Canver MC, Cushing MM, Vagelatos G, Vasovic LV. Visual evidence of a hemolytic transfusion reaction identified by blood bank testing after emergency blood transfusion. Transfusion. 2019;59(11):3301-3302.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019;17(2):446-456.

de Brot S, Grau-Roma L, Stirling-Stainsby C, Dettwiler M, Guscetti F, Meier D, et al. A Fibromyxoid Stromal Response is Associated with Muscle Invasion in Canine Urothelial Carcinoma. J Comp Pathol. 2019;169:35-46.

Hernandez A, Brandler TC, Zhou F, Moreira AL, Schatz-Siemers N, Simsir A. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma. Am J Clin Pathol. 2019;151(4):403-415.